Elizabeth Berry-Kravis

Co-Director, Molecular Diagnostics Section of the Genetic Laboratory · Rush University Medical Center

Credentials: · · · ·

History

Batten Disease Clinical Research Consortium
National Institute of Child Health and Human Development · U54
Project lead · $339.8K · Hugo w. Moser Res Inst Kennedy Krieger
2025–2030
A Non-Viral CRISPR-Mediated Genome Editing Delivery Platform as a Potential Therapy for Neurogenetic Diseases
National Center for Advancing Translational Sciences · UG3
PI · $30M · Yale University
2023–2027
Characterizing the Natural History of Fragile X Syndrome to Inform the Development of Intervention,Outcome Measures
NCBDDD · U01
Contact PI · $4.5M · Rush University Medical Center
2021–2027
Using Longitudinal Data to Characterize the Natural History of Fragile x Syndrome to Improve Services
NCBDDD · U01
Contact PI · $849.8K · Rush University Medical Center
2015–2024

An Open-Label Extension Study of BPN14770 in Subjects With Fragile X Syndrome
Principal investigator · Active not recruiting · Phase 3
Tetra Discovery Partners
2022–2027
A Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X Syndrome
Principal investigator · Completed · Phase 3
Tetra Discovery Partners
2022–2025
Investigation of Sulindac (HLX-0201) and Gaboxadol (HLX-0206) in Male Fragile X Syndrome Patients Aged 13-40
Principal investigator · Withdrawn · Phase 2
Healx Limited
2022
ERG/5-HTP in Fragile X Syndrome (FXS)
Principal investigator · Completed · Phase 2
Elizabeth Berry-Kravis
2021–2023